Prospective Study of Antiplatelet and Anticoagulation Therapy in Hereditary Haemorrhagic Telangiectasia
University Hospital, Clermont-Ferrand
100 participants
Apr 7, 2023
INTERVENTIONAL
Conditions
Summary
The goal of this clinical trial is to evaluate in real life, in patients with Hereditary Hemorrhagic Telangiectasia (HHT), the tolerance of the strategy of use of anticoagulant and/or antiplatelet, by comparing a new exposure period (first trimester of treatment) to a period of reference non-exposure (last trimester before start of treatment).
Eligibility
Inclusion Criteria4
- Patient with Rendu-Osler disease with an indication of antiplatelet and/or anticoagulant introduced for less than 3 months (inclusion period within 3 months of exposure)
- Age > 18 years old
- Patient able to understand and agree to participate in the study
- Affiliation to a social security system
Exclusion Criteria4
- Patient with an indication of antiplatelet and/or anticoagulant but for whom treatment has not been introduced or introduced for more than 3 months
- Refusal to participate
- Pregnant woman or who are breast feeding
- Patients under maintenance of justice, wardship or legal guardianship
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Monitoring: * hemoglobin and ferritin levels * transfusion or intravenous iron * hospitalization for bleeding or thrombose * digestive bleeding and/or another haemorrhagic accident * severity of epistaxis * quality of life
Locations(18)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05641142